Surgical Innovation Associates Raises $15 Million In Oversubscribed Series B Round, Appoints Veteran Medtech Ceo
Surgical Innovation Associates Raises $15 Million In Oversubscribed Series B Round, Appoints Veteran Medtech Ceo
12/16/21, 4:07 PM
Location
chicagoMoney raised
$15 million
Round Type
series b
Surgical Innovation Associates, Inc. (SIA), a growth-stage medical device company that manufacturers fully-resorbable, biosynthetic implants for the high-growth, multi-billion-dollar markets of plastic, reconstructive, and general surgery, today announced the successful close of its Series B round of financing.
Company Info
Location
chicago, illinois, united states
Additional Info
Founded in Chicago in 2016, SIA created the DuraSorb® product family and has led it from ideation through FDA 510k clearance, CE marking, and into the operating room. The company is based in Chicago, IL (USA) and DuraSorb is commercially available in the USA and Europe. Use of DuraSorb®, like any implantable medical device, carries risk of complications that may arise from the surgical implantation procedure or from the device itself. A full list of Warnings and Precautions is available in the Instructions for Use documents for US and EU surgeons. In the United States, the device has been cleared only for use in reinforcement of soft tissue where weakness exists, and remains investigational for specific applications in breast reconstruction and aesthetics.
Learn more at sia.health.